# Serina Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Serina Therapeutics, Inc.). ## Overview Serina Therapeutics, Inc. is a U.S.-based clinical-stage biotechnology company developing wholly owned drug candidates for neurological diseases and other indications. Its core platform, POZ, uses a synthetic poly(2-oxazoline) polymer to modify how drugs are loaded and released, with applications across small molecules, RNA-based therapeutics, and antibody-based drug conjugates. ## Products & services • POZ drug-delivery platform based on poly(2-oxazoline) • SER 252 lead candidate for advanced Parkinson’s disease • Neurology-focused pipeline of wholly owned product candidates • Preclinical and clinical-stage drug development programs • Collaboration/licensing opportunities around POZ-enabled assets - **POZ platform technology** (20%) — Synthetic polymer-based formulation technology used to improve drug loading and release control. - **Lead clinical candidate SER 252** (25%) — A neurological disease program intended for advanced Parkinson’s disease. - **Other product candidates** (35%) — Wholly owned preclinical and early clinical assets built on the POZ platform. - **Research and development services** (20%) — Internal discovery, preclinical testing, and clinical development activities. - POZ drug-delivery platform based on poly(2-oxazoline) - SER 252 lead candidate for advanced Parkinson’s disease - Neurology-focused pipeline of wholly owned product candidates - Preclinical and clinical-stage drug development programs - Collaboration/licensing opportunities around POZ-enabled assets ## Customers Serina does not yet sell approved products; its near-term counterparties are regulators, clinical investigators, contract manufacturers, and potential development partners. If its programs advance, the end customers would be patients, physicians, and third-party payors in neurological and other therapeutic markets. The company’s commercial model is therefore centered on drug approval, clinical validation, and potential partnering rather than direct product sales today. - **Patients with neurological diseases** (primary) — Future end users of approved therapies such as SER 252, especially in Parkinson’s disease and related indications. - **Physicians and specialty clinics** (primary) — Prescribers who would adopt the therapy if clinical data, safety, and convenience support use. - **Regulatory agencies** (primary) — FDA and other authorities review INDs, clinical data, and marketing applications that determine whether programs can advance. - **Pharmaceutical development partners** (secondary) — Potential collaborators or licensees that may fund, develop, or commercialize POZ-enabled candidates. - **Contract manufacturers** (secondary) — CMOs and API suppliers that produce clinical and future commercial material for the pipeline. - Patients with neurological diseases are the eventual end users - Physicians and treatment centers would prescribe approved therapies - FDA and other regulators gate clinical and commercial progress - Contract manufacturers support API and finished-product supply - Potential pharma partners may license or co-develop POZ assets ## Geography Serina is headquartered in the United States and its development, regulatory, and financing activities are centered there. The company’s programs are intended for U.S. and global regulatory pathways, so its commercial footprint will depend on where approvals are obtained and where partners choose to launch products. As a clinical-stage biotech, its geographic exposure is driven more by regulatory jurisdiction and manufacturing sourcing than by current sales geography. - Headquartered in the United States - Clinical and regulatory work is centered in the U.S. - Future commercialization could extend to ex-U.S. markets - Manufacturing may rely on third-party suppliers and CMOs - Geographic exposure is mainly regulatory, not sales-driven today ## Strategy Serina’s strategy is to advance POZ-enabled drug candidates through preclinical and clinical development, starting with SER 252. The company also seeks to preserve optionality through collaborations, licensing, and future commercialization partnerships while building the manufacturing, regulatory, and intellectual property foundation needed for approval. Capital raising remains central to funding development work and extending the pipeline. - **Advance SER 252 into clinical development** (short-term) — Lead program progress is the main value driver for a clinical-stage biotech. - **Expand the POZ-enabled pipeline** (medium-term) — A broader pipeline can diversify scientific risk and create more partnering options. - **Strengthen manufacturing and regulatory readiness** (medium-term) — Clinical and future commercial supply depend on reproducible processes and compliant facilities. - **Maintain financing flexibility** (short-term) — Development-stage biotech programs require ongoing external capital before product revenue exists. - Advance SER 252 through IND-enabling and clinical development - Use POZ to improve drug loading and release characteristics - Build a pipeline across multiple modalities and indications - Pursue collaborations or licensing to share development risk - Secure manufacturing, regulatory, and IP infrastructure - Raise capital to fund R&D and public-company operations ## Risks Serina faces the core risks of clinical-stage biotechnology: uncertain trial outcomes, regulatory delays, and the possibility that product candidates never reach approval. Its platform and lead program also depend on intellectual property protection, manufacturing execution, and access to capital, while any approved product would still face reimbursement and commercial adoption hurdles. The company’s recent clinical hold on SER 252 illustrates how formulation or regulatory questions can delay development even when the active drug mechanism is not the issue. - **Regulatory delay or clinical hold** [high] — Drug development depends on FDA acceptance of INDs and trial plans, which can be slowed by data or formulation questions. - **Clinical failure or weak efficacy/safety profile** [high] — The company’s value depends on demonstrating that POZ-enabled candidates are safe and effective in humans. - **Financing and dilution risk** [high] — As a pre-revenue biotech, Serina must raise external capital to fund R&D and operations. - **Intellectual property and freedom-to-operate risk** [medium] — The POZ platform and product candidates rely on patent protection and defense against third-party claims. - **Manufacturing and supply-chain execution risk** [medium] — Clinical and future commercial supply depend on third-party manufacturing and reproducible processes. - FDA review can delay or block INDs and clinical trials - Clinical data may not show acceptable safety or efficacy - Cash needs may force dilution or limit development scope - IP disputes could weaken exclusivity around POZ technology - Manufacturing or excipient issues can interrupt development ## Accounting Serina’s financial statements are shaped by development-stage biotech accounting, where most spending is expensed as research and development and revenue is limited or absent until partnering or commercialization occurs. Investors should watch estimates tied to stock-based compensation, warrant and financing instruments, and any fair-value measurements associated with mergers or capital raises, as these can materially affect reported results. Going-concern disclosure, accrued development costs, and any collaboration or grant revenue recognition are also important because they reflect the company’s funding runway and the timing of cash use. - **Research and development expense recognition** — Affects operating loss and comparability across periods - **Fair value of warrants and financing instruments** — Can distort net income/loss versus cash burn - **Stock-based compensation** — Affects reported operating expenses and dilution analysis - **Going-concern assessment** — Signals financing risk and potential future dilution - R&D expense recognition drives most operating cost reporting - Stock-based compensation can materially affect G&A and R&D - Warrants and financing instruments may require fair-value accounting - Grant or collaboration revenue depends on contract terms and milestones - Going-concern and liquidity disclosures are important for comparability --- *Last updated: 2026-04-29T04:58:09.028085+00:00*